ID8, Identitii, Quarterly Activity Report and Appendix 4C

for the period ending 31 December 2024
Highlights

• Reece O’Connell appointed as Non-Executive Director
• US market-entry progresses with acceptance into Investment NSW Program
• Commenced reporting New Zealand transactions to the NZ regulator
• Commenced SOC 2 information security compliance for US market-entry
• Sales activities momentum in Q2-25 remained strong
• Renamed the Identitii platform BNDRY and launched new website
• $1.8M raised in well supported placement
• Payments to suppliers and employees of $1.22M, stable q/o/q
• After quarter end:
• $0.5M annual licence fee received from Mastercard
• $1.0M R&D tax incentive rebate issued by the ATO
• FY24 R&D loan repaid to and renewed for FY25

New Director Appointment
In December 2024, the Company announced the appointment of Reece O’Connell, an
experienced fund manager, as Non-Executive Director, bringing capital markets and
investor relations skills, experience and network connections to the Identitii Board. Reece
specialises in recognising and funding early-stage technology companies, including
Arovella Therapeutics (ASX:ALA), Dimerix (ASX:DXB), Neurizon Therapeutics (ASX:NUZ, formerly PharmAust ASX:PAA), Orthocell (ASX:OCC), Race Oncology (ASX:RAC) and Respiri (ASX:RSH).

Patent Infringement Claim Update
The Company’s claim for patent infringement against JP Morgan Chase (JPMC), filed in
October 2023, remains pending in the United States District Court for the District of
Delaware. There is currently a motion to dismiss the case in front of the court that has
not yet been ruled upon. The Company hopes to receive a ruling soon.
The Company’s claim has already passed its first significant milestone, with the U.S.
Patent & Trademark Office (USPTO) denying a petition from JPMC to invalidate Identitii’s
patent in August last year. That outcome is significant in the context of how many
petitions are successful in invalidating a patent, with 68% of all petitions received by the
USPTO successful in the 12 months to September last year.